Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01290367




Registration number
NCT01290367
Ethics application status
Date submitted
3/02/2011
Date registered
7/02/2011
Date last updated
26/06/2020

Titles & IDs
Public title
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
Scientific title
A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain
Secondary ID [1] 0 0
MSB-DR001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Degenerative Disc Disease 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Single Dose MPCs Injection
Treatment: Surgery - Single injection of saline solution
Treatment: Surgery - Single injection of hyaluronic acid
Other interventions - Single Dose MPCs Injection

Experimental: High Dose MPCs - Injection of High Dose MPCs with Hyaluronic Acid

Experimental: Low Dose MPCs - Injection of Low Dose MPCs with Hyaluronic Acid

Sham Comparator: Saline injection - Injection of saline solution.

Placebo Comparator: Hyaluronic acid injection - Injection of hyaluronic acid solution


Other interventions: Single Dose MPCs Injection
Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

Treatment: Surgery: Single injection of saline solution
Intradiscal control injection with saline solution

Treatment: Surgery: Single injection of hyaluronic acid
Intradiscal control injection with hyaluronic acid

Other interventions: Single Dose MPCs Injection
Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).
Timepoint [1] 0 0
3 years
Secondary outcome [1] 0 0
To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.
Timepoint [1] 0 0
6 - 36 Months
Secondary outcome [2] 0 0
To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).
Timepoint [2] 0 0
1 - 36 Months

Eligibility
Key inclusion criteria
1. Male or females at least 18 years of age.

2. Have the ability to understand the requirements of the study, to provide written
informed consent, and to comply with the study protocol.

3. Have the ability to understand and provide written authorization for the use and
disclosure of personal health information (PHI) [per Health Insurance Portability and
Accountability Act (HIPAA) privacy ruling in the US].

4. Have chronic low back pain for at least 6 months.

5. Have documented symptomatic diagnosis of DDD of one level from L1-S1 as determined by
a change in disc hydration on MRI compared to normal disc with or without an annular
fissure or a contained disc herniation.

6. Have failed 3 months of non-operative low back pain management.

7. Disc height loss of <30% compared to a normal adjacent disc based upon radiographic
evaluation.

8. Pre-treatment baseline low back pain of at least 40 mm on a 100 mm visual analog
scale.

9. Low back pain greater than leg pain.

10. Pre-treatment baseline Oswestry Disability Index Questionnaire score of at least 30 on
the 100-point questionnaire.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Female subjects who are pregnant or nursing, or women planning to become pregnant
during the first year (12 months) following surgery.

2. Have a current or prior history within the last 3 years of neoplasm (excluding basal
cell carcinoma) and/or any active neoplasm within the last 24 months, prior to
screening.

3. Patients with compressive pathology due to stenosis or frankly herniated disc or
sequestered discs are not candidates.

4. Intact disc bulge/protrusion or focal herniation at the symptomatic level (s) > 3 mm
or presence of disc extrusion or sequestration.

5. Lumbar spondylitis or other undifferentiated spondyloarthropathy.

6. Have undergone a previous surgery at the involved levels.

7. Any lumbar intradiscal injection procedure (e.g., injection of corticosteroids,
methylene blue, dextrose, or glucosamine and chondroitin sulfate). Discography may be
performed, but must be done at least 2 weeks or more prior to the MPC injection
procedure.

8. Have an acute fracture of the spine at the time of enrollment in the study.

9. Have a history of epidural steroid injections within 1 week prior to study treatment.

10. Have a known history of hypersensitivity or anaphylactic reaction to murine or bovine
products or dimethyl sulfoxide (DMSO).

11. Have a positive screen for human immunodeficiency virus (HIV) antibodies.

12. Have a known history of hypersensitivity or anaphylactic reaction to Hyaluronan.

13. Have a current or prior history within the last 3 years of neoplasm (excluding basal
cell carcinoma) and/or any active neoplasm within the last 24 months, prior to
screening.

14. Have been a recipient of prior stem cell/progenitor cell therapy or other biological
intervention to repair the target intervertebral disc.

15. Are transient or has been treated in the last 6 months before enrollment for alcohol
and/or drug abuse in an inpatient substance abuse program.

16. Currently incarcerated (prisoners).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Medical Center - Clayton
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Virginia
Country [8] 0 0
United States of America
State/province [8] 0 0
Washington
Country [9] 0 0
United States of America
State/province [9] 0 0
West Virginia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Mesoblast, Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare two doses of immunoselected, culture-expanded,
nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control
intradiscal injections in subjects with chronic low back pain due to moderate Degenerative
Disc Disease (DDD) at one lumbar level from L1 to S1.

All investigational subjects in this study will undergo injection of either 6 million (M) or
18M cells in a hyaluronic acid carrier into the degenerated lumbar disc's nucleus pulposus.
All control subjects will undergo an intradiscal control injection with either saline or
hyaluronic acid only
Trial website
https://clinicaltrials.gov/show/NCT01290367
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Roger Brown
Address 0 0
Mesoblast, Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications